Cytovale

Cytovale is a commercial-stage diagnostics company addressing the critical unmet need for rapid, objective sepsis detection. Its flagship product, the IntelliSep test, runs on the proprietary Cytovale System and provides emergency department clinicians with a probability of sepsis with organ dysfunction within 3 days in about 8 minutes, enabling faster therapeutic intervention. The company's innovative approach leverages deformability cytometry to analyze immune cell biomechanics, offering a novel biomarker for sepsis. Cytovale is positioned to improve patient outcomes, reduce mortality, and increase hospital operational efficiency by transforming sepsis diagnosis from a clinical guess into a data-driven decision.

Proprietary diagnostic platform using deformability cytometry. It employs microfluidics, ultra-high-speed imaging, and machine learning to analyze the biomechanical properties (deformability) of white blood cells as a biomarker for immune activation in sepsis.

Cytovale competes in the sepsis diagnostics market against traditional methods like blood cultures and biomarkers (e.g., procalcitonin, lactate), which are slower or less specific. It also faces potential competition from other companies developing rapid molecular or host-response tests. Cytovale's primary competitive advantage is the speed (~8 minutes) and novel biomechanical mechanism of its FDA-cleared test.